Company intelligence / Profile preview

Xiling Lab

Chengdu, Sichuan, China

Ownership: Private
Development stage: Other

Overview

Xiling Lab has advanced its lead HER2-targeting eribulin ADC candidate SMP‑656 into Phase 1 clinical trials, demonstrating strong preclinical efficacy and safety. The company also has a small molecule program in clinical development for irritable bowel syndrome.

Therapeutic areas: GastroenterologyOncology
Modalities: Antibody-drug conjugateSmall molecule
Industry: Biotech

Partnerships

none publicly disclosed as of June 2025; recent financing led by Shenzhen Share Precision Medicine Venture Capital Partnership Enterprise and Sichuan Provincial Health and Pension Industry Equity Investment Fund Partnership Enterprise

Beyond the preview

Go deeper on Xiling Lab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiling Lab.

Explore the full profile